Methotrexate
(Unterschied zwischen Versionen)
K |
|||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA conventional pharmacology}} | ||
{{tp|p=32534807|t=2020. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.|pdf=|usr=008}} | {{tp|p=32534807|t=2020. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.|pdf=|usr=008}} | ||
{{ttp|p=32471659|t=2020. Silencing of immune activation with methotrexate in patients with COVID-19.|pdf=|usr=008}} | {{ttp|p=32471659|t=2020. Silencing of immune activation with methotrexate in patients with COVID-19.|pdf=|usr=008}} | ||
{{tp|p=32535597|t=2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.|pdf=|usr=008}} | {{tp|p=32535597|t=2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.|pdf=|usr=008}} | ||
Version vom 18. Januar 2021, 20:26 Uhr
| PHA conventional pharmacology |
32534807 2020. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.
| 32471659 2020. Silencing of immune activation with methotrexate in patients with COVID-19. |
32535597 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.
